CLINICAL TRIALS PROFILE FOR CONIVAPTAN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for conivaptan hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00057356 ↗ | Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure | Completed | Cumberland Pharmaceuticals | Phase 2 | 2002-11-01 | This is a randomized, double-blind, placebo-controlled, dose ranging pilot study to examine the effects of conivaptan in patients with acute decompensated heart failure. |
| NCT00379847 ↗ | An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia | Completed | Cumberland Pharmaceuticals | Phase 3 | 2004-02-01 | This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia. |
| NCT00435591 ↗ | A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia | Completed | Cumberland Pharmaceuticals | Phase 4 | 2007-01-01 | The study will evaluate the effectiveness and safety of multiple dosing regimens of IV conivaptan in subjects with euvolemic or hypervolemic hyponatremia |
| NCT00478192 ↗ | Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia | Completed | Cumberland Pharmaceuticals | Phase 3 | 2007-04-01 | The study is designed to assess the efficacy and safety of multiple infusions of conivaptan in subjects with euvolemic or hypervolemic hyponatremia |
| NCT00592475 ↗ | A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients | Completed | Cumberland Pharmaceuticals | Phase 2 | 2007-12-01 | To evaluate the safety of IV conivaptan in stable euvolemic or hypervolemic cirrhotic patients, and to characterize the effects of IV conivaptan on the hepatic hemodynamic response in patients with cirrhosis. |
| NCT00684164 ↗ | Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients | Withdrawn | Astellas Pharma Inc | Phase 3 | 2008-05-01 | Low sodium levels (hyponatremia) are a frequent occurrence in medically ill patients, and in particular those with neurological injury. Hyponatremia has been associated with worse outcome, problems with memory and concentration and impaired balance. Standard treatment for low sodium (salt) levels is to give the patient a salt containing solution thru a catheter (small flexible tube) in a vein in the arm or leg. One of the major complications of this treatment is excess body fluid which may cause heart problems or accumulation of fluid in the lungs and may require additional medications to remove extra water from the body. FDA approval has recently been granted for a new drug - Conivaptan - for use in hyponatremic conditions. Conivaptan works by excreting free water from the body and thereby produce concurrent rise in serum sodium concentrations. Conivaptan has not been evaluated specifically in patients with brain injuries. The primary objective of this study is to demonstrate the safety and efficacy of intravenous Conivaptan for the treatment of hyponatremia in patients with brain injury. If effective, Conivaptan may represent a safe treatment option. |
| NCT00684164 ↗ | Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients | Withdrawn | Columbia University | Phase 3 | 2008-05-01 | Low sodium levels (hyponatremia) are a frequent occurrence in medically ill patients, and in particular those with neurological injury. Hyponatremia has been associated with worse outcome, problems with memory and concentration and impaired balance. Standard treatment for low sodium (salt) levels is to give the patient a salt containing solution thru a catheter (small flexible tube) in a vein in the arm or leg. One of the major complications of this treatment is excess body fluid which may cause heart problems or accumulation of fluid in the lungs and may require additional medications to remove extra water from the body. FDA approval has recently been granted for a new drug - Conivaptan - for use in hyponatremic conditions. Conivaptan works by excreting free water from the body and thereby produce concurrent rise in serum sodium concentrations. Conivaptan has not been evaluated specifically in patients with brain injuries. The primary objective of this study is to demonstrate the safety and efficacy of intravenous Conivaptan for the treatment of hyponatremia in patients with brain injury. If effective, Conivaptan may represent a safe treatment option. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for conivaptan hydrochloride
Condition Name
Clinical Trial Locations for conivaptan hydrochloride
Trials by Country
Clinical Trial Progress for conivaptan hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for conivaptan hydrochloride
Sponsor Name
